Olsutamig

奥苏妥米单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameOlsutamig

Drug Alias NameAnti-PSMAxCD3 - Regeneron PharmaceuticalsREGN-4336

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-PSMAAnti-CD3

TargetsProstate-Specific Membrane AntigenT cell surface glycoprotein CD3

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesRegeneron Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-ResistantCarcinoma, Renal Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A